▲伯桢生物联合创始人、研发总监倪超博士（左）、药明生物副总裁、蛋白质科学部负责人吴健生博士（右）

Dr. Chao Ni, Vice President and R&D Director of bioGenous Biotechnologies (left), Dr. Jiansheng Wu, Vice President of WuXi Biologics and Head of the Protein Science Department (right)

伯桢生物致力于为生物医学科学研究、药物研发和临床精准医疗提供标准化、模块化、自动化类器官产品和技术支持。公司秉承“引领医药创新，共享模型价值”的愿景，以国际一流的研发科技人才为核心，以“全球领先类器官模型平台”为使命，坚持优质和高效的服务，切实提升客户新药研发效率和基础研究能力，让好药更早惠及百姓。

药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。

On April 26, 2023, bioGenous Technologies signed a strategic partnership agreement with WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) company, to collaborate in the development and manufacture of upstream GMP-grade raw materials for organoid culture. 

This strategic collaboration will leverage the advanced biopharmaceutical and protein science platforms of WuXi Biologics as well as the novel biomedical innovations and application of organoid technology platforms of bioGenous Technologies to jointly develop a large-scale production line for upstream GMP-grade raw materials for organoid culture. This collaboration is aimed at realizing an integrated system of the whole process from research and development to process standardization and GMP production. This collaboration will further promote the standardization and application of organoid technology in biologics, and accelerate innovations in both local and international biopharmaceutical industries.

In his comment, Dr. Ni expressed great optimism about the prospect of this strategic partnership with WuXi Biologics in championing cutting-edge innovations in organoid technology. Organoid technology, a revolutionary technology in the field of biomedicine, has great prospects for development and industrial application. In drug development, organoids have shown unique advantages in the preclinical evaluation of small molecule drugs, protein antibody drugs, conjugated drugs, and cell and gene drugs owing to the high mimicry of the primary human tissue or organ. However, as an emerging revolutionary model, organoid technology requires continuous optimization and standardization, especially since most of the upstream proteins needed for organoid cultures, such as cytokines and growth factors lack GMP standards. In the past, bioGenous Technologies and WuXi Biologics have previously cooperated in the development of highly stable proteins with superior activity. The current strategic cooperation will further expand the scope of cooperation by fully leveraging the superior edge and experience of bioGenous Technologies in the application of organoid technology, and the protein purification, development, manufacturing, and innovative drug discovery platforms of WuXi Biologics. This will accelerate innovation in the field of organoid technology and enhance the application of organoids in drug discovery and healthcare delivery systems.

bioGenous Technologies is committed to providing standardized organoid culture reagents, automated organoid systems, and technical support for biomedical research, drug development, and precision medicine. The company adheres to the vision of “leading biomedical innovation and creating shared value of experimental models”. Having excellent researchers as the core of its R & D and the establishment of leading organoid model platforms, bioGenous provides high-quality and efficient services using organoid technology to accelerate new drug research, drug testing, and basic sciences so that quality drugs can benefit the public early.

WuXi Biologics (stock code: 2269.HK) is a leading global contract research, development and manufacturing (CRDMO) company offering end-to-end solutions that enable partners to discover, develop, and manufacture biologics - from concept to commercialization – for the benefit of patients worldwide.